title: [Transfusions of rhesus-incompatible platelet concentrates in Rouen University Hospital: procedures and consequences].
abstract: BACKGROUND
  Guidelines for distribution and use of blood products have been established for both blood transfusion institution and hospitals, in particular for the use of Rh (D)-incompatible platelet concentrates. The aim of this study was to evaluate: 1) the rate of attribution for the Rh (D)-incompatible platelets concentrates, 2) the immunisation prophylaxis practices, 3) the immunological consequences using short and medium term follow-up of transfused patients.
  
  
  METHODS
  Patients with Rh (D)-incompatible platelets concentrate administered during the year 2003 at Rouen University Hospital were retrospectively selected. Patients on transfusion were described. The relationship of various factors with the injection as well as the appearance of allo-immunization was statistically tested.
  
  
  RESULTS
  During a year, 280 Rh (D)-incompatible platelets concentrates were administered to 67 patients. Immunisation prophylaxis by injection of Ig anti-D was not systematically performed. Four immunizations in the Rhesus group system were identified: 2 against D antigen (Ag), 1 against E Ag and 1 against C Ag. Immunisations against D Ag occurred for two younger women considered as immunodeficient. Immunization prophylaxis was more frequent in poly-transfused patients. However no difference was observed for the other factors.
  
  
  CONCLUSIONS
  Compatibility concerning Rhesus (D) is not always possible. The immunization against red cells persists, in particular against the antigens of the Rhesus group system and moreover for the immunodeficient patients. Recommendations for immunization prophylaxis by injection of specific anti-D immune-globulin (Ig) could be reconsidered.
authors.affiliation: Département d'épidémiologie et de santé publique, CHU, Rouen, France. pierre.chamouni@chu-rouen.fr
authors.forename: P
authors.initials: P
authors.lastname: Chamouni
authors.forename: V
authors.initials: V
authors.lastname: Josset
authors.forename: D
authors.initials: D
authors.lastname: Bastit
authors.forename: M P
authors.initials: MP
authors.lastname: Tavolacci
authors.forename: P
authors.initials: P
authors.lastname: Lenain
authors.forename: R
authors.initials: R
authors.lastname: Varin
authors.forename: P
authors.initials: P
authors.lastname: Czernichow
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001787:Blood Group Incompatibility / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D001788:Blood Grouping and Crossmatching; D002648:Child; D002675:Child, Preschool; D005260:Female; D006785:Hospitals, University / Q000706:statistics & numerical data*; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007518:Isoantibodies / Q000096:biosynthesis; D008297:Male; D016347:Medical Records Systems, Computerized; D008875:Middle Aged; D017713:Platelet Transfusion / Q000009:adverse effects* / Q000706:statistics & numerical data; D010983:Plateletpheresis; D012189:Retrospective Studies; D012203:Rh Isoimmunization / Q000209:etiology* / Q000517:prevention & control; D012204:Rh-Hr Blood-Group System / Q000276:immunology*; D018029:Rho(D) Immune Globulin
chemical_list: D007518:Isoantibodies; C061961:RHO(D) antibody; D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin